{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-18T17:18:35.364042+00:00","company":{"ticker":"PBSV","cik":1304161,"company_name":"Pharma-Bio Serv, Inc."},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"earnings_release","fact_key":"4d8af7c326b3cbcf1abec1fa2ba00e34e9eefa83","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2026-06-15T21:06:05+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $0.3 million","period_text":"the six months ended April 30, 2026","report_date":"2026-06-15","result_type":"reported_results","revenue_text":"approximately $5.0 million"},"claim":"Pharma-Bio Serv, Inc. reported the six months ended April 30, 2026 results: revenue approximately $5.0 million, net income approximately $0.3 million.","evidence_excerpt":"revenues for the three and six months ended April 30, 2026 were approximately $2.7 million and $5.0 million, respectively, representing increases of approximately $0.3 million and $0.1 million compared to the same periods last year. Net income for the three and six months ended April 30, 2026 was approximately $0.2 million and $0.3 million, respectively, representing increases of approximately $0.1 million and $0.2 million compared to the same periods last year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-26-005989","anchor_url":"https://secwatch.observer/filing/0001654954-26-005989#claim-4d8af7c326b3cbcf1abec1fa2ba00e34e9eefa83","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/0001654954-26-005989-index.htm"},{"fact_type":"earnings_release","fact_key":"25a278e3178d9c3bd8fcfa9f15ec919e4d4155b5","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2026-06-15T21:06:05+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $0.2 million","period_text":"the quarter ended April 30, 2026","report_date":"2026-06-15","result_type":"reported_results","revenue_text":"approximately $2.7 million"},"claim":"Pharma-Bio Serv, Inc. reported the quarter ended April 30, 2026 results: revenue approximately $2.7 million, net income approximately $0.2 million.","evidence_excerpt":"revenues for the three and six months ended April 30, 2026 were approximately $2.7 million and $5.0 million, respectively, representing increases of approximately $0.3 million and $0.1 million compared to the same periods last year. Net income for the three and six months ended April 30, 2026 was approximately $0.2 million and $0.3 million, respectively, representing increases of approximately $0.1 million and $0.2 million compared to the same periods last year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-26-005989","anchor_url":"https://secwatch.observer/filing/0001654954-26-005989#claim-25a278e3178d9c3bd8fcfa9f15ec919e4d4155b5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/0001654954-26-005989-index.htm"},{"fact_type":"earnings_release","fact_key":"6cc3440f14b3cff757094d35c27de96336285611","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2026-03-17T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$32,860","period_text":"quarter ended January 31, 2026","report_date":"2026-03-17","result_type":"reported_results","revenue_text":"approximately $2.3 million"},"claim":"Pharma-Bio Serv, Inc. reported quarter ended January 31, 2026 results: revenue approximately $2.3 million, net income $32,860.","evidence_excerpt":"biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2026 were approximately $2.3 million, a decrease of approximately $0.2 million when compared to the same period last year. Net income for the quarter ended January 31, 2026 was $32,860, an improvement of $24,324","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-26-002338","anchor_url":"https://secwatch.observer/filing/0001654954-26-002338#claim-6cc3440f14b3cff757094d35c27de96336285611","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426002338/0001654954-26-002338-index.htm"},{"fact_type":"shareholder_vote","fact_key":"48e5bfb5e59e634f8d5310c749edd8ca38655a14","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of the Plan Amendment","proposal_type":"equity_plan","results":[{"broker_non_votes":"1,714,854","subject":null,"votes_abstain":"3,854,521","votes_against":"5,127,032","votes_for":"7,523,008","votes_withheld":null}]},"claim":"Pharma-Bio Serv, Inc. shareholders approved Approval of the Plan Amendment.","evidence_excerpt":"The approval of the Plan Amendment received the following votes: Votes For Votes Against Abstain 7,523,008 5,127,032 3,854,521 There were 1,714,854 broker non-votes on this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-24-005476","anchor_url":"https://secwatch.observer/filing/0001654954-24-005476#claim-48e5bfb5e59e634f8d5310c749edd8ca38655a14","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495424005476/0001654954-24-005476-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f0286e71cafc8e0d15a12f3d9e93c06c7804549f","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-10-31","outcome":"passed","proposal_text":"Ratification of Crowe PR PSC as independent certified public accountants","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"3,853,221","votes_against":"1,500","votes_for":"14,364,694","votes_withheld":null}]},"claim":"Pharma-Bio Serv, Inc. shareholders approved Ratification of Crowe PR PSC as independent certified public accountants at the 2024-10-31 meeting.","evidence_excerpt":"The ratification of the selection of Crowe PR PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2024 received the following votes: Votes For Votes Against Abstain 14,364,694 1,500 3,853,221 There were no broker non-votes on this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-24-005476","anchor_url":"https://secwatch.observer/filing/0001654954-24-005476#claim-f0286e71cafc8e0d15a12f3d9e93c06c7804549f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495424005476/0001654954-24-005476-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a76f2dd5ee10e3689c96468bc237c4ab384b1640","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of Class II Directors","proposal_type":"director_election","results":[{"broker_non_votes":null,"subject":"Kirk Michel","votes_abstain":null,"votes_against":null,"votes_for":"12,647,540","votes_withheld":"3,857,021"},{"broker_non_votes":null,"subject":"Dov Perlysky","votes_abstain":null,"votes_against":null,"votes_for":"7,546,374","votes_withheld":"8,958,187"}]},"claim":"Pharma-Bio Serv, Inc. shareholders approved Election of Class II Directors.","evidence_excerpt":"Kirk Michel and Dov Perlysky received the following votes: Nominee Votes For Votes Withheld Kirk Michel 12,647,540 3,857,021 Dov Perlysky 7,546,374 8,958,187 There were 1,714,854 broker non-votes on this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-24-005476","anchor_url":"https://secwatch.observer/filing/0001654954-24-005476#claim-a76f2dd5ee10e3689c96468bc237c4ab384b1640","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495424005476/0001654954-24-005476-index.htm"},{"fact_type":"earnings_release","fact_key":"61c1d3fd51264d81ef26dcaf87726aa047ce3dea","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2024-03-18T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $270,700","period_text":"the quarter ended January 31, 2024","report_date":"2024-03-18","result_type":"reported_results","revenue_text":"approximately $2.4 million"},"claim":"Pharma-Bio Serv, Inc. reported the quarter ended January 31, 2024 results: revenue approximately $2.4 million, net income approximately $270,700.","evidence_excerpt":"today announced that revenues for the quarter ended January 31, 2024 were approximately $2.4 million, a decrease of approximately $1.9 million when compared to the same period last year. Net loss for the quarter ended January 31, 2024 was approximately $270,700 compared to a net income of approximately $426,400 for the same period last year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-24-003318","anchor_url":"https://secwatch.observer/filing/0001654954-24-003318#claim-61c1d3fd51264d81ef26dcaf87726aa047ce3dea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495424003318/0001654954-24-003318-index.htm"},{"fact_type":"earnings_release","fact_key":"4a26bfc4e0b5a368f943505a90a5a3e541495d94","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2024-01-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $1.3 million","period_text":"FY ended October 31, 2023","report_date":"2024-01-29","result_type":"reported_results","revenue_text":"approximately $17.0 million"},"claim":"Pharma-Bio Serv, Inc. reported FY ended October 31, 2023 results: revenue approximately $17.0 million, net income approximately $1.3 million.","evidence_excerpt":"Pharma-Bio Serv, Inc. (\"Pharma-Bio Serv\" or the \"Company\") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2023 were approximately $17.0 million, a decrease of approximately $2.4 million when compared to last year. Additionally, net income for the year ended October 31, 2023 was approximately $1.3 million, an improvement of approximately $0.3 million when compared to last year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-24-001022","anchor_url":"https://secwatch.observer/filing/0001654954-24-001022#claim-4a26bfc4e0b5a368f943505a90a5a3e541495d94","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495424001022/0001654954-24-001022-index.htm"},{"fact_type":"earnings_release","fact_key":"f96b95427f7d74ecd71adfa93a6b21d25e61c158","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2023-09-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three and nine months ended July 31, 2023","report_date":"2023-09-14","result_type":"reported_results","revenue_text":null},"claim":"Pharma-Bio Serv, Inc. reported financial results for the three and nine months ended July 31, 2023.","evidence_excerpt":"On September 14, 2023, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the three and nine months ended July 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-011895","anchor_url":"https://secwatch.observer/filing/0001654954-23-011895#claim-f96b95427f7d74ecd71adfa93a6b21d25e61c158","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423011895/0001654954-23-011895-index.htm"},{"fact_type":"earnings_release","fact_key":"5c0e9354f8240c13b9da84c8c4f7ebd401bf052e","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $0.4 and $0.8 million, respectively","period_text":"the three and six months ended April 30, 2023","report_date":"2023-06-14","result_type":"reported_results","revenue_text":"approximately $4.6 and $8.8 million, respectively"},"claim":"Pharma-Bio Serv, Inc. reported the three and six months ended April 30, 2023 results: revenue approximately $4.6 and $8.8 million, respectively, net income approximately $0.4 and $0.8 million, respectively.","evidence_excerpt":"revenues for the three and six months ended April 30, 2023 were approximately $4.6 and $8.8 million, respectively, a decrease of approximately $0.4 and $1.2 million, respectively, when compared to the same periods last year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-23-008031","anchor_url":"https://secwatch.observer/filing/0001654954-23-008031#claim-5c0e9354f8240c13b9da84c8c4f7ebd401bf052e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423008031/0001654954-23-008031-index.htm"},{"fact_type":"shareholder_vote","fact_key":"17c55cf7159c0d9f33b027a6c4298d65e8e6d6ee","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2023-05-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-31","outcome":"passed","proposal_text":"Ratification of Crowe PR PSC as independent auditors","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"3,852,921","votes_against":"1,492,688","votes_for":"14,344,226","votes_withheld":null}]},"claim":"Pharma-Bio Serv, Inc. shareholders approved Ratification of Crowe PR PSC as independent auditors at the 2023-05-31 meeting.","evidence_excerpt":"The ratification of the selection of Crowe PR PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2023 received the following votes: Votes For Votes Against Abstain 14,344,226 1,492,688 3,852,921 There were no broker non-votes on this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-007428","anchor_url":"https://secwatch.observer/filing/0001654954-23-007428#claim-17c55cf7159c0d9f33b027a6c4298d65e8e6d6ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423007428/0001654954-23-007428-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9aa99a4de9663bb8374882293a7972619cd48fc9","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2023-05-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-31","outcome":"passed","proposal_text":"Election of Irving Wiesen as a Class I director","proposal_type":"director_election","results":[{"broker_non_votes":"515,852","subject":"Irving Wiesen","votes_abstain":null,"votes_against":null,"votes_for":"7,477,036","votes_withheld":"11,696,947"}]},"claim":"Pharma-Bio Serv, Inc. shareholders approved Election of Irving Wiesen as a Class I director at the 2023-05-31 meeting.","evidence_excerpt":"Irving Wiesen was elected as a Class I director by a plurality of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote. Mr. Wiesen shall serve as a Class I director until the 2026 Annual Meeting of Stockholders or until his successor is duly elected and qualified. The votes for this proposal were as follows: Nominee Votes For Votes Withheld Irving Wiesen 7,477,036 11,696,947 There were 515,852 broker non-votes on this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-007428","anchor_url":"https://secwatch.observer/filing/0001654954-23-007428#claim-9aa99a4de9663bb8374882293a7972619cd48fc9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423007428/0001654954-23-007428-index.htm"},{"fact_type":"earnings_release","fact_key":"219dcca3afc62c7674522ab35f238b003914ddcf","cik":1304161,"ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2023-03-17T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $0.4 million","period_text":"quarter ended January 31, 2023","report_date":"2023-03-17","result_type":"reported_results","revenue_text":"approximately $4.2 million"},"claim":"Pharma-Bio Serv, Inc. reported quarter ended January 31, 2023 results: revenue approximately $4.2 million, net income approximately $0.4 million.","evidence_excerpt":"revenues for the quarter ended January 31, 2023 were approximately $4.2 million, a net decrease of approximately $0.8 million when compared to the same period last year. Net income for the quarter ended January 31, 2023 was approximately $0.4 million, an increase of approximately $0.1 million when compared to the same period last year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-23-003136","anchor_url":"https://secwatch.observer/filing/0001654954-23-003136#claim-219dcca3afc62c7674522ab35f238b003914ddcf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423003136/0001654954-23-003136-index.htm"}]}